Xiaobing Qian

Xiaobing Qian is the Chief Development Officer of Degron Therapeutics. Dr. Qian will lead the company’s translational medicine, preclinical development, and early clinical development. In this role, Dr. Qian will focus on driving Degron’s lead programs to IND filing in 2024 and maximizing the value of the programs with optimized clinical development plan.

Prior to joining Degron Therapeutics, Dr. Qian served as VP Clinical Development and VP Global Medical Evaluations & Strategy at Boston Pharmaceuticals, she led the successful completion of clinical programs and was the clinical member of the BD diligence team that evaluated more than 300 programs and closed 5 deals in 12 months. Dr. Qian was Executive Director, Early Clinical Development and Head Translational Medicine Strategy and Medical Director at Regeneron Pharmaceuticals from 2008-2018, where she demonstrated her extensive expertise and successfully led efforts to identify new product opportunities through integrated scientific, medical, and clinical/regulatory development analysis across multiple therapeutic areas. She and her team helped advance more than 20 drug candidates into clinical development and 6 marketed drugs. Dr. Qian was also a Medical Director of two clinical programs at Regeneron Pharmaceuticals and led First in Human and proof of concept clinical trials globally. While working at CGI Pharmaceuticals, Dr. Qian led the discovery and development of several kinase inhibitor drugs in oncology and autoimmune diseases, and contributed to multiple partnerships and funding successes, including a $500 million Genentech/CGI BTK collaboration. Dr. Qian is also a pioneering scientist and inventor of AAV gene therapy for hemophilia. She has multiple patents and publications from her innovative work in gene therapy, small molecule kinase inhibitors, and biological drugs.

Dr. Xiaobing Qian received her MD degree from Peking University Medical School, and her PhD degree in Biochemistry and Molecular Biology from University of Illinois College of Medicine, Chicago. She conducted her postdoctoral research at the Gladstone Institutes at the University of California, San Francisco. Dr. Qian is a member of the TRIUM Global EMBA Class 2024, a premier program delivered by NYU Stern/London School of Economics/Paris HEC.